Valerio Therapeutics
Created in 2014
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
935 8,027 8,027Activities
Technologies
Entity types
Location
49 Bd du Général Martial Valin, 75015 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 60
SIREN
410910095Engaged corporates
1
1 0Added in Motherbase
3 years, 6 months ago
biotech Value proposition
Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions.
Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR).
DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments.
Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases precision therapeutics from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners.
The Company's portfolio is based on platONTM, Valerio Therapeutic's decoy oligonucleotide platform.
PlatONTM is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides.
The Company's portfolio includes:
- AsiDNATM, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNATM is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy.
- A new family of compounds are positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. VIO-01, is currently being optimized in a preclinical phase.
The Company is convinced of the significant therapeutic potential of its technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer and inflammatory disease treatments.
Oncology, DNA Damage Response, Epigenetics, Translational research, Partnering, M&A, Licensing, DNA repair, HDAC, Cancer, oligonucleotide, DDR, and DNA DecoyOriginal language
Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions.
Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR).
DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments.
Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases precision therapeutics from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners.
The Company's portfolio is based on platONTM, Valerio Therapeutic's decoy oligonucleotide platform.
PlatONTM is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides.
The Company's portfolio includes:
- AsiDNATM, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNATM is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy.
- A new family of compounds are positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. VIO-01, is currently being optimized in a preclinical phase.
The Company is convinced of the significant therapeutic potential of its technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer and inflammatory disease treatments.
Valerio Therapeutics
https://valeriotx.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 19 Sep 2017 | | |